Although several small molecule pan-ErbB inhibitors are now in clinical trials evaluation for cancer therapy [46], our data suggests that Ang-(1–7), that also has significant anti-proliferative actions together with an acceptable safety profile in human clinical trials [47], might represent an attractive alternative treatment option for tumours reliant on ErbB receptors for growth and development. Here, EGFR is linked to cancer.